Skip to main content

Market Overview

Celcuity Teams Up With MD Anderson, Novartis, Puma Biotech To Study New Drug Regimen In Breast Cancer


Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clinical trial.

  • The open-label Phase 2 trial will evaluate the efficacy and safety of two targeted therapies, Novartis' Tabrecta, a c-Met inhibitor, and Puma's Nerlynx, a pan-HER inhibitor, in patients with previously treated metastatic HER2-negative breast cancer selected with Celcuity's CELsignia Multi-Pathway Activity Test.
  • Under the agreement, MD Anderson will serve as the sponsor, and Celcuity will fund the patient-related trial costs.
  • Tabrecta and Nerlynx are currently approved by the FDA to treat non-small cell lung cancer and HER2-positive breast cancer, respectively.
  • Celcuity expects to obtain interim results 12 to 15 months after the protocol is activated and final results 12 to 15 months later.
  • Enrollment will begin in the second quarter of 2021.
  • Price Action: CELC shares are up 6.3% at $ 14.62 in premarket on the last check Wednesday.

Related Articles (NVS + PUMA)

View Comments and Join the Discussion!

Posted-In: breast cancer Phase 2 Clinical TrialBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at